原著論文

（南学正臣）

1) Tanaka S, Tanaka T, Kawakami T, Takano H, Sugahara M, Saito H, Higashijima Y,

Yamaguchi J, Inagi R, Nangaku M. Vascular adhesion protein-1 enhances neutrophil infiltration

via generation of hydrogen peroxide in renal ischemia-reperfusion injury. Kidney Int in press

2) Yamaguchi S, Waki K, Tomizawa N, Waki H, Nannya Y, Nangaku M, Kadowaki T, Ohe K.

Previous dropout from diabetic care as a predictor of patients' willingness to use mobile

applications for self-management: a cross-sectional study. J Diabetes Investig in press

3) Akizawa T, Tsubakihara Y, Nangaku M, Endo Y, Nakajima H, Kohno T, Imai Y, Kawase N,

Hara K, Lepore J, Cobitz A. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl

Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. Am J

Nephrol 45, 127-135, 2016

4) Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, Nishi S, Yoshimura A,

Sato H, Ogahara S, Sasatomi Y, Kataoka Y, Ueda S, Koyama A, Maruyama S, Nangaku M, Imai

E, Matsuo S, Tomino Y; Refractory Nephrotic Syndrome Study Group. Mizoribine therapy

combined with steroids and mizoribine blood concentration monitoring for idiopathic

membranous nephropathy with steroid-resistant nephrotic syndrome. Clin Exp Nephrol 2016

Oct 25. [Epub ahead of print]

5) Bazzi C, Usui T, Rizza V, Casellato D, Gallieni M, Nangaku M. Urinary

N-acetyl-β-glucosaminidase and eGFR may identify patients to be treated with

immuno-suppression at diagnosis in idiopathic membranous nephropathy. Nephrology (Carlton).

2016 Oct 20. doi: 10.1111/nep.12952. [Epub ahead of print]

6) Kushida N, Nomura S, Mimura I, Fujita T, Yamamoto S, Nangaku M, Aburatani H.

Hypoxia-Inducible Factor-1α Activates the Transforming Growth Factor-β/SMAD3 Pathway in

Kidney Tubular Epithelial Cells. Am J Nephrol 44, 276-285, 2016

7) Sugawara Y, Honda K, Katagiri D, Nakamura M, Kawakami T, Nasu R, Hayashi A, Shintani

Y, Tojo A, Noiri E, Kurokawa M, Fukayama M, Nangaku M. Umbilical Cord Blood

Transplantation-associated Nephrotic Syndrome Successfully Treated by Low-density

Lipoprotein Apheresis. Intern Med 55, 2831-2836, 2016

8) Nasu K, Hanafusa N, Nangaku M. Selective plasma exchange can reduce auto-antibodies in

patients with bullous pemphigoid without affecting factor XIII and fibrinogen. J Clin Apher

2016 Oct 6. doi: 10.1002/jca.21513. [Epub ahead of print]

9) Asada T, Isshiki R, Hayase N, Sumida M, Inokuchi R, Noiri E, Nangaku M, Yahagi N, Doi K.

Impact of clinical context on acute kidney injury biomarker performances: differences between

neutrophil gelatinase-associated lipocalin and L-type fatty acid-binding protein. Sci Rep 6,

33077, 2016

10) Makita N, Sato T, Yajima-Shoji Y, Sato J, Manaka K, Eda-Hashimoto M, Ootaki M,

Matsumoto N, Nangaku M, Iiri T. Analysis of the V2 Vasopressin Receptor (V2R) Mutations

Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a

Non-peptide V2R Agonist. J Biol Chem 291, 22460-22471, 2016

11) Waki K, Fujiu K, Hayashi A, Kimura S, Kobayashi H, Nangaku M, Kadowaki T, Ohe K.

DialBetics: Smartphone-Based Self-Management for Type 2 Diabetes Patients on Insulin

Injections. J Diabetes Sci Technol 10, 804-5, 2016

12) Okubo K, Kamiya M, Urano Y, Nishi H, Herter JM, Mayadas T, Hirohama D, Suzuki K,

Kawakami H, Tanaka M, Kurosawa M, Kagaya S, Hishikawa K, Nangaku M, Fujita T, Hayashi

M, Hirahashi J. Lactoferrin Suppresses Neutrophil Extracellular Traps Release in Inflammation.

EBioMedicine 10, 204-15, 2016

13) Omura T, Watanabe E, Otsuka Y, Yoshida Y, Kato H, Nangaku M, Miyata T, Oda S.

Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient

with non-Shiga toxin-associated bacterial enteritis: A case report. Medicine 95, e4104, 2016

14) Iwagami M, Yasunaga H, Matsui H, Horiguchi H, Fushimi K, Noiri E, Nangaku M, Doi K.

Impact of end-stage renal disease on hospital outcomes among patients admitted to intensive

care units: A retrospective matched-pair cohort study. Nephrology (Carlton). 2016 Jun 1. doi:

10.1111/nep.12830. [Epub ahead of print]

15) Miyata T, Uchida Y, Yoshida Y, Kato H, Matsumoto M, Kokame K, Fujimura Y, Nangaku

M. No association between dysplasminogenemia with p.Ala620Thr mutation and atypical

hemolytic uremic syndrome. Int J Hematol 104, 223-7, 2016

16) Fukuma S, Shimizu S, Niihata K, Sada KE, Yanagita M, Hatta T, Nangaku M, Katafuchi R,

Fujita Y, Koizumi J, Koizumi S, Kimura K, Fukuhara S, Shibagaki Y. Development of quality

indicators for care of chronic kidney disease in the primary care setting using electronic health

data: a RAND-modified Delphi method. Clin Exp Nephrol 2016 May 4. [Epub ahead of print]

17) Iwagami M, Yasunaga H, Noiri E, Horiguchi H, Fushimi K, Matsubara T, Yahagi N,

Nangaku M, Doi K. Potential Survival Benefit of Polymyxin B Hemoperfusion in Septic Shock

Patients on Continuous Renal Replacement Therapy: A Propensity-Matched Analysis. Blood

Purif 42, 9-17, 2016

18) Saito H, Hanafusa N, Kishikawa J, Noiri E, Sunami E, Ishihara S, Watanabe T, Nangaku M.

Ulcerative colitis with hepatitis B virus infection treated successfully by granulocyte monocyte

apheresis. J Clin Apher 2016 Feb 15. doi: 10.1002/jca.21450. [Epub ahead of print]

19) Yamashita T, Noiri E, Hamasaki Y, Matsubara T, Ishii T, Yahagi N, Nangaku M, Doi K.

Erythropoietin concentration in acute kidney injury is associated with insulin-like growth

factor-binding protein-1. Nephrology in press

20) Isshiki R, Asada T, Sato D, Sumida M, Hamasaki Y, Inokuchi R, Matsubara T, Ishii T,

Yahagi N, Nangaku M, Noiri E, Doi K. Association of Urinary Neutrophil

Gelatinase-Associated Lipocalin with Long-Term Renal Outcomes in Icu Survivors: a

Retrospective Observational Cohort Study. Shock 2016 Jul;46(1):44-51.

21) Iwagami M, Yasunaga H, Noiri E, Horiguchi H, Fushimi K, Matsubara T, Yahagi N,

Nangaku M, Doi K. Potential Survival Benefit of Polymyxin B Hemoperfusion in Septic Shock

Patients on Continuous Renal Replacement Therapy: A Propensity-Matched Analysis. Blood

Purif 42, 9-17, 2016

22) Katagiri D, Hamasaki Y, Doi K, Negishi K, Sugaya T, Nangaku M, Noiri E. Interstitial

renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive

amine oxidase inhibition. Kidney Int 89, 374-385, 2016

23) Tojo A, Asaba K, Kinugasa S, Ikeda Y, Shintani Y, Fukayama M, Nangaku M. The reduced

expression of proximal tubular transporters in acquired Fanconi syndrome with κ light chain

deposition. Med Mol Morphol 49, 48-52, 2016

24) Hirakawa Y, Hanafusa N, Nangaku M. Correction of metabolic alkalosis and elevated

calcium levels by sodium chloride in a hemodialysis patients with inadequate chloride intake.

Ther Apher Dial 20, 86-87, 2016

25) Mayumi K, Yamashita T, Hamasaki Y, Noiri E, Nangaku M, Yahagi N, Doi K. Impact of

continuous renal replacement therapy intensity on septic acute kidney injury. Shock 45,

133-138, 2016

26) Imai E, Maruyama S, Nangaku M, Hirakata H, Hayashi T, Narita I, Kono H, Nakatani E,

Morita S, Tsubakihara Y, Akizawa T. Rationale and study design of a randomized controlled

trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention

of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).

Clin Exp Nephrol 20, 71-76, 2016

27) Kinoshita Y, Arai M, Ito N, Takashi Y, Makita N, Nangaku M, Shinoda Y, Fukumoto S.

High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in

patients with bone metastases from solid tumors. Endocr J 63, 479-484, 2016

（合田亘人）

1) Semba H, Takeda N, Isagawa T, Sugiura Y, Honda K, Wake M, Miyazawa H, Yamaguchi Y,

Miura M, Jenkins D, Choi H, Kim JW, Asagiri M, Cowburn AS, Abe H, Soma K, Koyama K,

Katoh M, Sayama K, Goda N, Johnson RS, Manabe I, Nagai R, Komuro I. HIF-1-PDK1 axis

induced active glycolysis plays an essential role in macrophage migratory capacity. Nat.

Commun. 7:11635, 2016.

2) Karigane D, Kobayashi H, Morikawa T, Ootomo Y, Sakai M, Nagamatsu G, Kubota Y, Goda

N, Matsumoto M, Nishimura EK, Soga T, Otsu K, Suematsu M, Okamoto S, Suda T, Takubo K.

p38α Activates Purine Metabolism to Initiate Hematopoietic Stem/Progenitor Cell Cycling in

Response to Stress. Cell Stem Cell. 19(2):192-204, 2016.

3) Hachiya R, Shiihashi T, Shirakawa I, Iwasaki Y, Matsumura Y, Oishi Y, Nakayama Y,

Miyamoto Y, Manabe I, Ochi K, Tanaka M, Goda N, Sakai J, Suganami T, Ogawa Y. The H3K9

methyltransferase Setdb1 regulates TLR4-mediated inflammatory responses in macrophages.

Sci. Rep. 6:28845, 2016.

4) Takikawa A, Mahmood A , Nawaz A, Kado T, Okabe K, Yamamoto S, Arif A, Senda S,

Tsuneyama K, Ikutani M, Watanabe Y, Igarashi Y, Nagai Y, Takatsu K, Koizumi K, Imura J,

Goda N, Sasahara M, Matsumoto M, Saeki K, Nakagawa T, Fujisaka S, Usui I, Tobe K. HIF-1α

in myeloid cells promotes adipose tissue remodeling toward insulin resistance. Diabetes

65(12):3649-3659, 2016.

5) Yamano E, Sugimoto M, Hirayama A, Kume S, Yamato M, Jin G, Tajima S, Goda N, Iwai K,

Fukuda S, Yamaguti K, Kuratsune H, Soga T, Watanabe Y, Kataoka Y. Index markers of chronic

fatigue syndrome with dysfunction of TCA and urea cycles. Sci. Rep. 6:34990, 2016.

6) Arai T, Ono Y, Arimura Y, Sayama K, Suzuki T, Shinjo S, Kanai M, Abe S, Semba K, Goda N.

Type I neuregulin1α is a novel local mediator to suppress hepatic gluconeogenesis in mice. Sci.

Rep. 7:42959, 2017.

（武田憲彦）

1) Goodwin J, Neugent ML, Lee SY, Choe JH, Choi H, Jenkins DMR, Ruthenborg RJ,

Robinson MW, Jeong JY, Wake M, Abe H, Takeda N, Endo H, Inoue M, Xuan Z, Yoo H, Chen

M, Ahn JM, Minna JD, Helke KL, Singh PK, Shackelford DB, Kim JW. Distinct Metabolic

Phenotypes within Non-small Cell 1 Lung Cancer Define Selective Vulnerability to Glycolytic

Inhibition of Lung Squamous Cell Carcinoma. Nature Communicatioons. 2017 (in press).

2) Katoh M, Takeda N, Arimoto T, Abe H, Oda K, Osuga Y, Fujii T and Komuro I.

Bevacizumab-related microvascular angina and its management with nicorandil. Int Heart J.

2017 (in press)

3) Matsuda J, Fujiu K, Roh S, Tajima M, Maki H, Kojima T, Ushiku T, Nawata K, Takeda N,

Watanabe M, Akazawa H, Komuro I. Cardiac Sarcoidosis Diagnosed by Incidental Lymph Node

Biopsy. Int Heart J. 58(1):140-143, 2017.

4) Ohmae S, Noma N, Toyomoto M, Shinohara M, Takeiri M, Fuji, Takemoto K, Iwaisako K,

Fujita T, Takeda N, Kawatani M, Aoyama M, Hagiwara M, Ishihama Y and Asagiri M.

Actin-binding protein coronin 1A controls osteoclastic bone resorption by regulating lysosomal

secretion of cathepsin K. Sci Rep. Mar 16;7:41710, 2017.

5) Chino H, Amano Y, Yamauchi Y, Matsuda J, Takeda N, Tanaka G, Takai D, Nagase T.

Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for

advanced non-small cell lung cancer. J Thorac Dis. 8(9):2646-2650, 2016.

6) Semba H, Takeda N, Isagawa T, Sugiura Y, Honda K, Wake M, Miyazawa H, Yamaguchi Y,

Miura M, Jenkins DM, Choi H, Kim JW, Asagiri M, Cowburn AS, Abe H, Soma K, Koyama K,

Katoh M, Sayama K, Goda N, Johnson RS, Manabe I, Nagai R and Komuro I. HIF-1-PDK1

axis induced active glycolysis plays an essential role in macrophage migratory capacity. Nature

Communications 7, 11635, 2016.

7) Abe H., Iguchi N, Utanohara Y, Takada K, Hen Y, Machida H, Takeda N, Sumiyoshi T.

Planimetry of the orifice area in aortic valve stenosis using phase-contrast cardiac magnetic

resonance imaging. Int Heart J. 2017 (in press)

総 説

（南学正臣）

1) Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S.

Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin

Adv Hematol Oncol 14 Suppl 11, 2-15, 2016

2) Mimura I, Tanaka T, Nangaku M. New insights into molecular mechanisms of epigenetic

regulation in kidney disease. Clin Exp Pharmacol Physiol 2016 Aug 25. doi:

10.1111/1440-1681.12663. [Epub ahead of print]

3) Basile DP, Bonventre JV, Mehta R, Nangaku M, Unwin R, Rosner MH, Kellum JA, Ronco C;

ADQI XIII Work Group. Progression after AKI: Understanding Maladaptive Repair Processes

to Predict and Identify Therapeutic Treatments. J Am Soc Nephrol 27, 687-697, 2016

4) Humphreys BD, Cantaluppi V, Portilla D, Singbartl K, Yang L, Rosner MH, Kellum JA,

Ronco C; Acute Dialysis Quality Initiative (ADQI) XIII Work Group. Targeting Endogenous

Repair Pathways after AKI. J Am Soc Nephrol 27, 990-8, 2016

5) Rabb H, Griffin MD, McKay DB, Swaminathan S, Pickkers P, Rosner MH, Kellum JA,

Ronco C; Acute Dialysis Quality Initiative Consensus XIII Work Group. Inflammation in AKI:

Current Understanding, Key Questions, and Knowledge Gaps. J Am Soc Nephrol 27, 371-9,

2016

6) Okusa MD, Rosner MH, Kellum JA, Ronco C; Acute Dialysis Quality Initiative XIII

Workgroup. Therapeutic Targets of Human AKI: Harmonizing Human and Animal AKI. J Am

Soc Nephrol 27, 44-8, 2016

7) Matejovic M, Ince C, Chawla LS, Blantz R, Molitoris BA, Rosner MH, Okusa MD, Kellum

JA, Ronco C; ADQI XIII Work Group. Renal Hemodynamics in AKI: In Search of New

Treatment Targets. J Am Soc Nephrol 27, 49-58, 2016

（武田憲彦）

1) Takeda N, Maemura K. Circadian clock and the onset of cardiovascular events. Hypertens

Res. 39(6):383-90, 2016.

2) 武田憲彦 . 酸素から視た生活習慣病の新しい理解 . ファルマシア Vol.53. No.3,

p228-230, 2017

著 書

（武田憲彦）

1) Takeda N. The roles of hypoxic responses during the pathogenesis of cardiovascular diseases.

Chronic Inflammation p675-683, 2016. (Springer, Edited by Miyasaka Masayuki, Takatsu

Kiyoshi)

その他

（南学正臣）

国際学会

（招待講演）

1. 南学正臣

2. Oxygen biology and epigenetics in the kidney.

3. Seminar

4. Mar 25, 2016

5. National Clinical Research Center of Kidney Diseases, Nanjing, China

（招待講演）

1. 南学正臣

2. Hypoxia and persistent inflammation in CKD

3. Plenary lecture XVIII International Congress on Nutrition and Metabolism in

Renal Disease,

4. April 22, 2016

5. Okinawa, Japan

（招待講演）

1. 南学正臣

2. Development of novel drugs targeting renal hypoxia and anaemia.

3. 53rd European Renal Association/European Dialysis and Transplantation

Association

4. May 24, 2016

5. Vienna, Austria

（招待講演）

1. 南学正臣

2. Anemia management update.

3. CME. 15th Asian Pacific Congress of Nephrology

4. Sept 17, 2016

5. Perth, Australia

（招待講演）

1. 南学正臣

2. Epigenetics of renal disease.

3. Symposium; 15th Asian Pacific Congress of Nephrology

4. Sept 20, 2016

5. Perth, Australia

（招待講演）

1. 南学正臣

2. Hypoxia-inducible factors in diabetic nephropathy.

3. 50th American Society of Nephrology

4. Nov 19, 2016

5. Chicago, U.S.A

（招待講演）

1. 南学正臣

2. Novel therapeutic targets in PKD, DKD, and CKD: mitochondria, ER, and oxygen

metabolism.

3. Seminar

4. Nov 21, 2016

5. Yale University, New Haven, U.S.A.

（招待講演）

1. 南学正臣

2. Oxygen biology in the kidney.

3. Invited Lecture, NTU-UTokyo Joint Conference

4. Dec 1, 2016

5. Taiwan

（合田亘人）

（招待講演）

1. Goda N

2. Metabolic diseases and HIF-1

3. 第 89回生化学会大会；シンポジウム

4. 2016年 9月 26日

5. 仙台国際センター

（招待講演）

1. 合田 亘人

2. 低酸素応答システムが拓く代謝性疾患の新しい病態理解

3. 第 20回酸素ダイナミクス研究会

4. 2016年 11月 19日

5. 東京

（武田憲彦）

国際学会

（招待講演）

1. Takeda N

2. HIF-1-PDK1 axis induced active glycolysis plays an essential role in macrophage

migratory capacity.

3. 2016 HDRC International Symposium

4. 2016年 6月 17日

5. Inha Univ, Incheon, Korea.

（招待講演）

1. Takeda N

2. HIF-1-PDK1 axis induced active glycolysis plays an essential role in macrophage

migratory capacity.

3. Keystone Symposium “Adaptaions to Hypoxia in Physiology and Disease”

4. 2017年 3月 9日

5. Whistler Conference Centre, Whistler, British Columbia, Canada

国内学会

（招待講演）

1. 武田憲彦

2. “心血管リモデリングにおける炎症細胞・低酸素シグナルの役割”

3. 第 48回日本動脈硬化学会総会学術集会；シンポジウム（動脈硬化と炎症）

4. 2016年 7月 14日

5. 京王プラザホテル、東京

（招待講演）

1. 武田憲彦

2. HIF-1-PDK1経路を介した代謝リプログラミングはマクロファージ遊走能を促進する

3. 第 37回日本肥満学会；シンポジウム（イムノメタボリズムと肥満症）

4. 2016年 10月 8日

5. 東京ファッションタウン、東京

(招待講演)

1. 武田憲彦

2. Perivascular accumulation of M1 macrophages elicits the development of immature

vascular formation.

3. 第 24回日本血管生物医学会学術集会；シンポジウム

4. 2016年 12月 10日

5. 長崎ブリックホール、長崎

（招待講演）

1. 武田憲彦

2. マクロファージ活性化における細胞内グルコース代謝の役割

3. 第 20回日本適応医学会学術集会；シンポジウム 糖尿病の病態解明を巡る新たな展開

4. 2016年 12月 16日

5. 東京コンベンションホール、東京

1. 武田憲彦

2. Switching of two HIF- isforms regulates inflammatory processes and cardiac

remodeling.

3. 第 52回 高血圧関連疾患モデル学会

4. 2016年 9月 22日

5. 秋葉原UDX、東京.

1. 武田憲彦

2. The Role of Eosinophils in Pulmonary Arterial Remodelling

3. 第 81回 日本循環器学会学術集会；シンポジウム 臨床に還元する血管生物学の最新サ

イエンス

4. 2017年 3月 17日

5. ホテル日航金沢、金沢

1. 武田憲彦

2. 低酸素誘導性肺血管リモデリングにおける炎症細胞の役割

3. 第 9 回 日本生理学会大会；シンポジウム 酸素濃度変化が起点となる心血管生理調節

機構

4. 2017年 3月 30日

5. アクトシティ浜松、静岡

1. 安部 元, 武田 憲彦, 砂河 孝行, 仙波 宏章, 相馬 桂, 小山 雄広, 和氣 正樹, 加藤 愛

巳, 中釜 悠, 真鍋 一郎, 永井 良三, 小室 一成

2. 心臓リモデリングにおけるマクロファージ低酸素シグナルの役割

3. 第 89回日本生化学会大会

4. 2016年 9月 25日

5. 仙台国際センター

1. 砂河孝行, 武田憲彦, 仙波宏章，小山雄広, 安部 元, 相馬 桂, 和氣正樹, 加藤愛巳, 森岡

勝樹, 真鍋一郎, 前村浩二, 永井良三, 小室一成

2. マクロファージ微小環境適応における転写制御機構

3. 第 89回日本生化学会大会

4. 2016年 9月 25日

5. 仙台国際センター

1. Takayuki Isagawa, Norihiko Takeda , Hiroaki Semba, Hajime Abe, Katsura Soma,

Takehiro Koyama, Masaki Wake, Manami Kato, Masaki Morioka, Ichiro Manabe, Ryozo

Nagai, and Koji Maemura.

2. Comprehensive analysis of HIF-1α target genes in macrophage adaptation for the

microenvironment

3. The 24th Annual Meeting of the Japanese Vascular Biology and Medicine

Organization The 14th Korea-Japan Joint Symposium on Vascular Biology

4. 2016年 12月 8日

5. 長崎ブリックホール

1. 安部 元, 武田 憲彦, 砂河 孝行, 仙波 宏章, 相馬 桂, 小山 雄広, 和氣 正樹, 加藤 愛

巳, 中釜 悠, 真鍋 一郎, 永井 良三, 小室 一成

2. 圧負荷後心臓リモデリングにおけるマクロファージ低酸素シグナルの役割

3. 第 39回日本高血圧学会

4. 2016年 10月 2日

5. 仙台国際センター

1. 安部 元, 武田 憲彦, 仙波 宏章, 相馬 桂, 小山 雄広, 和氣 正樹, 加藤 愛巳, 中釜 悠,

真鍋 一郎, 永井 良三, 小室 一成

2. 心臓リモデリングにおいて Ly6C highマクロファージは HIF-1α-OncostatinMシグナ

ルを介して心保護的に作用する

3. 第 20回 日本心血管内分泌代謝学会学術総会

4. 2016年 12月 16日

5. 東京コンベンションホール

1. Abe H, Takeda N, Isagawa T, Semba H, Soma K, Koyama K, Wake M, Katoh M,

Manabe I, Nagai R, Komuro I

2. Roles of Ly6Chi monocytes hypoxia signaling in cardiac remodeling.

3. Keystone Symposium “Adaptaions to Hypoxia in Physiology and Disease”

4. 2017年 3月 6日

5. Whistler Conference Centre, Whistler, British Columbia, Canada

1. 加藤 愛巳, 武田 憲彦, 安部 元, 相馬 桂, 小山 雄広, 和氣 正樹, 中釜 悠, 砂河 孝行,

仙波 宏章, 小室 一成

2. 心臓リバースリモデリング過程における心筋代謝・ミトコンドリア機能の役割

3. 第 39回日本分子生物学会年会

4. 2016年 11月 30日

5. パシフィコ横浜

1. Soma K, Takeda N, Isagawa T, Abe H, Semba H, Koyama K, Wake M, Kato M,

Manabe I, Nagai R, Komuro I

2. The Role of Eosinophils in Hypoxia Induced Pulmonary Arterial Remodelling

3. European Society of Cardiology Congress 2016

4. 2016年 8月 29日

5. Fiera Roma

1. Soma K, Takeda N, Isagawa T, Abe H, Semba H, Koyama K, Wake M, Kato M,

Nakagama Y, Manabe I, Nagai R, Komuro I

2. The Role of Eosinophils in Hypoxia Induced Pulmonary Arterial Remodeling

3. The 24th Annual Meeting of the Japanese Vascular Biology and Medicine

Organization The 14th Korea-Japan Joint Symposium on Vascular Biology

4. 2016年 12月 10日

5. 長崎ブリックホール

「受賞」

（武田憲彦）

高血圧関連疾患モデル学会 第一回 永井賞